Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation

Atovaquone, a US Food and Drug Administration–approved antiparasitic drug previously shown to reduce interleukin-6/STAT3 signaling in myeloma cells, is well tolerated, and plasma concentrations of 40 to 80 µM have been achieved with pediatric and adult dosing. We conducted preclinical testing of ato...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood advances 2019-12, Vol.3 (24), p.4215-4227
Hauptverfasser: Stevens, Alexandra M., Xiang, Michael, Heppler, Lisa N., Tošić, Isidora, Jiang, Kevin, Munoz, Jaime O., Gaikwad, Amos S., Horton, Terzah M., Long, Xin, Narayanan, Padmini, Seashore, Elizabeth L., Terrell, Maci C., Rashid, Raushan, Krueger, Michael J., Mangubat-Medina, Alicia E., Ball, Zachary T., Sumazin, Pavel, Walker, Sarah R., Hamada, Yoshimasa, Oyadomari, Seiichi, Redell, Michele S., Frank, David A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Atovaquone, a US Food and Drug Administration–approved antiparasitic drug previously shown to reduce interleukin-6/STAT3 signaling in myeloma cells, is well tolerated, and plasma concentrations of 40 to 80 µM have been achieved with pediatric and adult dosing. We conducted preclinical testing of atovaquone with acute myeloid leukemia (AML) cell lines and pediatric patient samples. Atovaquone induced apoptosis with an EC50
ISSN:2473-9529
2473-9537
DOI:10.1182/bloodadvances.2019000499